Cannabics Pharmaceuticals Debt To Equity vs. EBITDA
| CNBX Stock | USD 0.01 0.00 0.00% |
For Cannabics Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cannabics Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cannabics Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cannabics Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cannabics Pharmaceuticals over time as well as its relative position and ranking within its peers.
Cannabics |
Cannabics Pharmaceuticals EBITDA vs. Debt To Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cannabics Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Cannabics Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Cannabics Pharmaceuticals is rated below average in debt to equity category among its peers. It is rated fourth in ebitda category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cannabics Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cannabics Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Cannabics EBITDA vs. Debt To Equity
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Cannabics Pharmaceuticals |
| = | 0.48 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Cannabics Pharmaceuticals |
| = | (3.52 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Cannabics EBITDA Comparison
Cannabics Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Cannabics Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cannabics Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cannabics Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Cannabics Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Cannabics Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. Cnbx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.
Cannabics Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cannabics Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cannabics Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cannabics Pharmaceuticals' important profitability drivers and their relationship over time.
Use Cannabics Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cannabics Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cannabics Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Cannabics Pharmaceuticals Pair Trading
Cannabics Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Cannabics Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cannabics Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cannabics Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cannabics Pharmaceuticals to buy it.
The correlation of Cannabics Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cannabics Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cannabics Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cannabics Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cannabics Pharmaceuticals position
In addition to having Cannabics Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Discretionary ETFs Thematic Idea Now
Consumer Discretionary ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Consumer Discretionary ETFs theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Discretionary ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Cannabics Pink Sheet Analysis
When running Cannabics Pharmaceuticals' price analysis, check to measure Cannabics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannabics Pharmaceuticals is operating at the current time. Most of Cannabics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cannabics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannabics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cannabics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.